Thursday, January 23, 2025

CATEGORY

Biogen

Mexico Greenlights LEQEMBI as First Alzheimer’s Progression-Slowing Treatment

Key TakeawaysLEQEMBI’s approval addresses a critical need in Mexico, where Alzheimer’s accounts for the majority of dementia cases. The drug’s ability to reduce...

Biogen Japan Launches Innovative APOE Research Initiative

Biogen Japan has announced a groundbreaking research initiative focused on the APOE gene, a critical factor in Alzheimer's disease (AD) progression. Spearheaded by CEO...

Dapirolizumab Pegol Boosts Lupus Treatment Efficacy in Phase 3 Study

Key TakeawaysDZP achieved a 14.6% higher BICLA response rate at 48 weeks compared to SOC alone. Participants on DZP experienced a 50% reduction...

Samsung Bioepis and Biogen Launch OPUVIZ in Europe, Enhancing Treatment Options for Retinal Disorders

Key TakeawaysHealthcare providers can incorporate OPUVIZ as a reliable and cost-effective alternative to Eylea, expanding treatment options for patients. Patients may benefit from...

LEQEMBI Autoinjector Set to Revolutionize Alzheimer’s Treatment Options

Key TakeawaysLEQEMBI's subcutaneous delivery method could reduce hospital visits and enhance patient adherence. The autoinjector targets early Alzheimer's stages, aiming to prolong therapeutic...

Felzartamab Shows Promise in Treating IgA Nephropathy

Key TakeawaysFelzartamab reduced proteinuria significantly, showing approximately a 50% reduction persisting 18 months after the last dose. Kidney function remained stable throughout the...

Eisai and Biogen Challenge Australia’s Initial Rejection of Alzheimer’s Drug Lecanemab

Key TakeawaysEisai and Biogen have announced plans to appeal the Therapeutic Goods Administration's (TGA) initial decision to deny registration for lecanemab in Australia,...

Eisai and Biogen to Appeal TGA Decision on Lecanemab for Alzheimer’s Treatment in Australia

Key TakeawaysAustralia's Therapeutic Goods Administration (TGA) has temporarily denied approval for lecanemab, Eisai and Biogen's monoclonal antibody for early-stage Alzheimer's disease. Eisai and...

Biogen Receives FDA Breakthrough Therapy Designation for Felzartamab in Kidney Transplant Antibody-Mediated Rejection

Key TakeawaysFelzartamab, Biogen’s investigational anti-CD38 monoclonal antibody, gains FDA Breakthrough Therapy Designation for treating antibody-mediated rejection (AMR) in kidney transplant patients. Clinical data...

Biogen Presents Positive Data for Higher Dose Nusinersen in SMA at World Muscle Congress

Key TakeawaysHigher dose nusinersen shows improved efficacy and safety in patients with spinal muscular atrophy (SMA), both treatment-naïve and previously treated, per new...

Amyotrophic Lateral Sclerosis Treatment Advances: Tofersen’s Impact on Survival and Quality of Life

Key TakeawaysThe G-BA's assessment of Tofersen highlights significant survival and quality of life improvements for amyotrophic lateral sclerosis patients with SOD1 mutations, particularly...

Lupus: UCB and Biogen Announce Positive Results for Dapirolizumab Pegol in SLE

Key TakeawaysDapirolizumab pegol demonstrated clinical improvement in moderate-to-severe SLE patients. The drug also showed positive outcomes in reducing disease activity and flares. No...

Biosimilar OPUVIZâ„¢ Receives Positive CHMP Opinion for Aflibercept-Based Treatment in Ophthalmology

Key TakeawaysOPUVIZâ„¢, a biosimilar referencing aflibercept (Eylea), has received a positive recommendation from the EMA's CHMP for the treatment of several retinal disorders. ...

Spinal Muscular Atrophy Treatment Advances with Biogen’s Higher Dose Nusinersen Showing Significant Motor Function Improvements

Key TakeawaysBiogen's Phase 2/3 DEVOTE study demonstrated that a higher dose regimen of nusinersen significantly improves motor function in infants with spinal muscular...

Alzheimer’s Treatment Leqembi® (Lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain

Alzheimer’s disease (AD) has taken another significant step forward in treatment, with the authorization of Leqembi® (lecanemab) in Great Britain for the treatment of...

Latest news